Canadian Imperial Bank of (NYSE: CM) Commerce is offering $6,439,000 ($6.44 million) of senior global medium-term digital basket-linked notes. Payments depend on the performance of a weighted basket of equity indexes through the determination date, giving investors an outcome tied to index performance rather …
Medicus Pharma Ltd. (NASDAQ: MDCX) shares closed down 34% at $0.17 following a worldwide licensing agreement with Pfizer for the early-stage CD228V ADC asset PF-08046031.
Hutchmed (China) Limited (NASDAQ: HCM) shares closed up 17% at $14.11 after entering an exclusive ex-China development and commercialization license with GSK for HMPL-A830, receiving $110 million upfront and up to $1.3 billion in total milestones plus royalties.
Aptevo Therapeutics, Inc. (NASDAQ: APVO) shares closed down 34% at $1.71 despite reporting interim RAINIER data in frontline TP53-mutated AML showing 93% clinical benefit and 79% CR/CRi among 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) shares closed down 29% at $0.14 as the company is set to execute a 1-for-20 reverse stock split on September 7, 2026.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 31% at $12.78 as the company advances its CyPath Lung platform for post-therapeutic lung cancer monitoring.
Biotech news over September 3 and 4, 2026 spanned a wide range of developments, from a new FDA approval and a major licensing deal to a clinical trial miss and several financing and corporate updates across more than a dozen companies.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares closed down 44% at $14.85 after its trial for Angelman syndrome failed to meet its primary endpoint, marking a clinical setback for the program.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales involving 584 shares at prices between $6.49 and $14.
Senti Biosciences, Inc. (NASDAQ: SNTI) raised $2 million via senior secured convertible notes issued to NSG BioInnovation Fund and established a $2.5 million equity agreement with a Celadon affiliate contingent on its pending merger.